← Back to Portfolio

Hydra Biosciences

Hydra is using its expertise in the Transient Receptor Potential (TRP) family of ion channels to discover novel drugs to treat pain, inflammation, cardiovascular conditions and other diseases. TRP channels offer numerous drug discovery opportunities in multiple areas of human disease. Hydra’s most advanced programme is in Phase I clinical trials. The company also has two ongoing collaborations with Boehringer Ingelheim.

Location Cambridge, Massachusetts
CEO Russell Herndon
Partner Vincent Miles
Website www.hydrabiosciences.com